{"id":"NCT00996164","sponsor":"Sprout Pharmaceuticals, Inc","briefTitle":"Fixed 100 mg Every Evening of Flibanserin vs Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder","officialTitle":"A Twenty-four Week, Randomized, Double-blind, Placebo Controlled, Safety and Efficacy Trial of Flibanserin (100 Milligrams) Administered Orally Once Daily in Premenopausal Women With Hypoactive Sexual Desire Disorder in the United States","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-10","primaryCompletion":"2010-12","completion":"2011-02","firstPosted":"2009-10-16","resultsPosted":"2014-05-19","lastUpdate":"2014-05-19"},"enrollment":1090,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Sexual Dysfunctions, Psychological"],"interventions":[{"type":"DRUG","name":"Flibanserin","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"flibanserin 100 mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The object of this trial is to assess the safety and efficacy of a 24 week course of flibanserin for the treatment of hypoactive sexual desire disorder in premenopausal women.","primaryOutcome":{"measure":"The Change From Baseline to Week 24 in the Score of the Female Sexual Function Index Desire Domain.","timeFrame":"24 weeks","effectByArm":[{"arm":"Flibanserin 100 mg","deltaMin":1,"sd":0.1},{"arm":"Placebo","deltaMin":0.7,"sd":0.1}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":75,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":543},"commonTop":["somnolence","dizziness","nausea","fatigue","upper respiratory tract infection"]}}